PL362375A1 - Zmodyfikowana leptyna o obniżonej immunogeniczności - Google Patents

Zmodyfikowana leptyna o obniżonej immunogeniczności

Info

Publication number
PL362375A1
PL362375A1 PL36237502A PL36237502A PL362375A1 PL 362375 A1 PL362375 A1 PL 362375A1 PL 36237502 A PL36237502 A PL 36237502A PL 36237502 A PL36237502 A PL 36237502A PL 362375 A1 PL362375 A1 PL 362375A1
Authority
PL
Poland
Prior art keywords
reduced immunogenicity
modified leptin
leptin
modified
immunogenicity
Prior art date
Application number
PL36237502A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Tim Jones
Stephen Williams
Anita Hamilton
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL362375A1 publication Critical patent/PL362375A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
PL36237502A 2001-02-06 2002-02-05 Zmodyfikowana leptyna o obniżonej immunogeniczności PL362375A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102618 2001-02-06
EP01103954 2001-02-19
PCT/EP2002/001188 WO2002062833A2 (en) 2001-02-06 2002-02-05 Modified leptin with reduced immunogenicity

Publications (1)

Publication Number Publication Date
PL362375A1 true PL362375A1 (pl) 2004-10-18

Family

ID=26076461

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36237502A PL362375A1 (pl) 2001-02-06 2002-02-05 Zmodyfikowana leptyna o obniżonej immunogeniczności

Country Status (12)

Country Link
US (1) US20040072219A1 (pl)
EP (1) EP1387856A2 (pl)
JP (1) JP2004532618A (pl)
KR (1) KR20030074788A (pl)
CN (1) CN1491232A (pl)
BR (1) BR0207018A (pl)
CA (1) CA2437265A1 (pl)
HU (1) HUP0402071A2 (pl)
MX (1) MXPA03006989A (pl)
PL (1) PL362375A1 (pl)
RU (1) RU2003125638A (pl)
WO (1) WO2002062833A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
JP4756813B2 (ja) 2000-05-22 2011-08-24 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) レセプターを用いた相互作用の捕捉法
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
WO2009108340A2 (en) * 2008-02-27 2009-09-03 Temple University - Of The Commonwealth System Of Higher Education Leptin agonist and methods of use
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
EP2482833A4 (en) * 2009-07-01 2013-05-01 Univ Temple LEPTIN AGONIST AND METHOD OF USE
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
CN114634552B (zh) * 2022-04-14 2022-12-13 中国农业大学 一种抗肥胖十三肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6225446B1 (en) * 1995-12-06 2001-05-01 Schering Corporation Mutational variants of mammalian proteins
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
PL362411A1 (pl) * 2001-02-06 2004-11-02 Merck Patent Gmbh Zmodyfikowany czynnik wzrostu neuronów pochodzenia mózgowego (BDNF) o obniżonej immunogeniczności

Also Published As

Publication number Publication date
US20040072219A1 (en) 2004-04-15
WO2002062833A3 (en) 2003-10-30
WO2002062833A2 (en) 2002-08-15
RU2003125638A (ru) 2005-03-10
CA2437265A1 (en) 2002-08-15
CN1491232A (zh) 2004-04-21
HUP0402071A2 (hu) 2005-01-28
EP1387856A2 (en) 2004-02-11
JP2004532618A (ja) 2004-10-28
MXPA03006989A (es) 2003-11-18
KR20030074788A (ko) 2003-09-19
BR0207018A (pt) 2004-02-03

Similar Documents

Publication Publication Date Title
IL227966A0 (en) Vaccination kit
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
HUP0402471A3 (en) Vaccine
HUP0402259A3 (en) Vaccines
GB0407935D0 (en) Vaccine
EP1459776A4 (en) SYRINGE
HUP0303372A3 (en) Vaccine
GB0121171D0 (en) Vaccine
MXPA03006989A (es) Leptina modificada con inmunogenicidad reducida.
HU0400176V0 (en) Improved gasketseal
HUP0401121A3 (en) Modified thrombopoietin with reduced immunogenicity
GB0105238D0 (en) Vaccines
GB0128651D0 (en) Syringe
HUP0303523A3 (en) Modified insulin with reduced immunogenicity
GB0113552D0 (en) Vaccines
AU2002302785A1 (en) Vaccines
TW494875U (en) Sunshade
GB0112989D0 (en) Sunshade
AU2479P (en) Crackerjack xTriticosecale
GB0103867D0 (en) Vaccine
GB0130823D0 (en) Vaccine
GB0124137D0 (en) Vaccine
GB0128312D0 (en) Vaccine
GB0115496D0 (en) Vaccine

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)